Diagnosis and initiation of treatment in Parkinson's disease

18Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Parkinson's disease (PD) is the most common cause of parkinsonism, yet the diagnosis and management can be a challenge. The United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria and dopamine transporter/single-photon emission computed tomography (DaT-SPECT) are diagnostic aids that can improve diagnostic accuracy. Even though PD is a progressive disease, for years, physicians and patients have delayed treatment until functional disability occurs. However, studies of monoamine oxidase-type B (MAO-B) inhibitors, dopamine agonists, and levodopa, all of which can be used as initial therapy, have demonstrated that PD patients receiving treatment do better than those who do not receive treatment, and some studies have shown that those receiving treatment earlier do better long term. Therefore, the management strategy for PD has moved toward earlier initiation of treatment. Although treatment for each patient should be individualized and based on their specific symptoms, severity, and lifestyle, in general MAO-B inhibitors may be used initially to treat mild symptoms, adding a dopamine agonist in younger patients or levodopa in older patients, as symptoms become more severe. © 2011 Informa Healthcare USA, Inc.

Cite

CITATION STYLE

APA

Lyons, K. E., & Pahwa, R. (2011). Diagnosis and initiation of treatment in Parkinson’s disease. International Journal of Neuroscience, 121(SUPPL. 2), 27–36. https://doi.org/10.3109/00207454.2011.620197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free